Q2 Earnings Forecast for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – Analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for shares of OPKO Health in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will post earnings of ($0.08) per share for the quarter, down from their prior forecast of ($0.07). HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health’s Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.31) EPS.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million.

Other research analysts have also issued research reports about the company. Barrington Research reiterated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Friday, February 28th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday.

OPKO Health Trading Up 1.0 %

Shares of OPK stock opened at $1.94 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health has a 1 year low of $0.86 and a 1 year high of $2.04. The stock has a fifty day moving average of $1.56 and a two-hundred day moving average of $1.55. The firm has a market capitalization of $1.32 billion, a PE ratio of -10.21 and a beta of 1.63.

Institutional Investors Weigh In On OPKO Health

Hedge funds have recently bought and sold shares of the business. Rubric Capital Management LP lifted its stake in OPKO Health by 9.6% in the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after acquiring an additional 4,284,336 shares in the last quarter. Barclays PLC lifted its stake in OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after acquiring an additional 329,870 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in OPKO Health by 736.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after acquiring an additional 217,450 shares in the last quarter. Intech Investment Management LLC purchased a new stake in OPKO Health in the 3rd quarter worth about $190,000. Finally, FMR LLC lifted its stake in OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 11,089 shares in the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 500,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were bought at an average cost of $1.56 per share, with a total value of $780,000.00. Following the completion of the transaction, the chief executive officer now directly owns 212,411,477 shares of the company’s stock, valued at approximately $331,361,904.12. This trade represents a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have bought 1,389,971 shares of company stock valued at $2,124,442. Corporate insiders own 47.26% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.